CD8A and neoplasm: CD8-enhanced pMHCI ligands are recognized at lower concentrations, induce significantly more cytokine production, enhance CTL proliferation and are better at priming human CTL directly ex vivo. These findings indicate a novel mechanism that could enable boosting of specific cytotoxic immunity, an approach that might be especially pertinent in the context of anti-tumour CTL responses.